Description
COMPOSITION:
Each LuciGil tablet contains: 44.2mg Gilteritinib Fumarate equivalent to Gilteritinib ……… 40mg
INDICATION:
LuciGil is a kinase inhibitor indicated for the treatment of adult patients who have relapsed or refractory acute myeloid leukemia (AML) with a FLT3 mutation as detected by an FDA-approved test.
DOSAGE AND USE:
The recommended starting dose of LuciGil is 120 mg orally once daily with or without food. In the absence of disease progression or unacceptable toxicity, treatment for a minimum of 6 months is recommended to allow time for a clinical response.
Tablet should be swallowed whole & not chewed or crushed.
STORAGE:
in a dry place and store at 20°C to 25°C.
MANUFACTURED AND MARKETED BY:
LUCIUS PHARMACEUTICALS(LAO) CO., LTD
No.26, Thongmang village, Xaythany district, Vientiane Capital, Laos
WARNING:
Keep medicine out of the reach of Children. Do not administered LuciGil in Pregnancy and Lactation patient treatment.
Reviews
There are no reviews yet.